SIX1 as a Novel Immunohistochemical Marker in the Differential Diagnosis of Rhabdomyosarcoma

Fetal Pediatr Pathol. 2023 Oct;42(5):723-734. doi: 10.1080/15513815.2023.2214806. Epub 2023 May 24.

Abstract

Background: Differential diagnosis of rhabdomyosarcoma (RMS) is challenging. Sineoculis homeobox homolog 1 (SIX1) is an oncogene involved in skeletal muscle differentiation. We compared protein expression patterns of SIX1 in RMS and its most common differential diagnoses. Methods: SIX1 immunohistochemistry in 36 RMS and in 33 tumors from seven differential diagnostic subtypes were evaluated. The fraction of SIX1 positive tumor cells was scored by three independent observers. Results: A majority (75%) of the evaluated RMS expressed SIX1 in at least 50% of tumor cells and all except one RMS had more than 25% positive tumor cells. Neuroblastoma had less than 1% SIX1 positive tumor cells. Gonadoblastoma, malignant rhabdoid tumor, and Ewing sarcoma had 10% or less positive tumor cells. Pleuropulmonary blastoma exhibited 26-50% positive tumor cells and synovial sarcoma >50% positive cells. Conclusion: SIX1 immunohistochemistry is positive in most RMS, and occasionally in some tumors within the differential diagnoses of RMS.

Keywords: A-RMS; E-RMS; Rhabdomyosarcoma; SIX1.

MeSH terms

  • Biomarkers, Tumor* / metabolism
  • Cell Differentiation
  • Diagnosis, Differential
  • Homeodomain Proteins
  • Humans
  • Immunohistochemistry
  • Rhabdomyosarcoma* / diagnosis
  • Rhabdomyosarcoma* / pathology

Substances

  • Biomarkers, Tumor
  • SIX1 protein, human
  • Homeodomain Proteins